| Autor: |
Kuntalee Rangnoi, Suthinee Soponpong, Nuchira Takheaw, Koollawat Chupradit, Piyarat Nimmanpipug, Thanathat Pamonsupornwichit, Nutjeera Intasai, Montarop Yamabhai, Weeraya Thongkum, Umpa Yasamut, Chatchai Tayapiwatana |
| Rok vydání: |
2021 |
| Předmět: |
|
| DOI: |
10.21203/rs.3.rs-964906/v1 |
| Popis: |
Domain 1 of CD147 participates in matrix metalloproteinase (MMP) production and is a candidate for targeted therapy to prevent cancer invasion and metastasis. A functional mouse anti-CD147 monoclonal antibody, M6-1B9, was found to recognize domain 1 of CD147, and its respective mouse single-chain variable fragment (ScFvM61B9) was subsequently generated. The EDLGS epitope candidate for M6-1B9 was identified using the phage display peptide technique in this study. For future clinical applications, humanized ScFv specific to domain 1 of CD147 (HuScFvM61B9) was partially adopted from the hypervariable sequences of parental mouse ScFvM61B9 and grafted onto suitable human immunoglobulin frameworks. Molecular modelling and simulation were performed in silico to generate the conformational structure of HuScFvM61B9. These results elucidated the amino acid residues that contributed to the interactions between CDRs and the epitope motif. The expressed HuScFvM61B9 specifically interacted with CD147 at the same epitope as the original mAb, M6-1B9, and retained immunoreactivity against CD147 in SupT1 cells. Binding affinity of HuScFvM61B9 by biolayer interferometry was higher than the predicted one. should be considered a potential therapeutic antibody. As domain 1 is responsible for cancer invasion and metastasis, HuScFvM61B9 would be a candidate for cancer targeted therapy in the future. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
